Non-small cell lung carcinoma

This phase 2 trial tests whether a vaccine made from immune cell-derived exosomes can slow cancer growth in people with advanced non-small cell lung cancer who have responded to initial chemotherapy. Participants receive low-dose cyclophosphamide followed by weekly injections of …

This completed Phase 4 trial tested two different doses of chemotherapy (standard and low-dose) combined with the immunotherapy drug Sintilimab in 20 people with advanced squamous non-small cell lung cancer. The goal was to see if the lower-dose combination could shrink tumors an…

This study tests a new drug combination for people with a specific type of advanced lung cancer (EGFR-mutant non-small cell lung cancer). The two drugs, LY3295668 and osimertinib, work by blocking enzymes that help cancer cells grow. The goal is to find the safest dose and see if…

This study looked at whether a special care plan led by a geriatrician and a nurse could improve survival and quality of life for older adults (70+) with advanced cancer. 792 patients with breast, colorectal, lung, prostate, bladder, ovarian cancer, or lymphoma took part. The app…

Researchers are testing an experimental immunotherapy called GNR-051 in adults with advanced lung cancer, kidney cancer, or melanoma that has returned or not responded to other treatments. The Phase 1 trial aims to find the highest dose people can tolerate and to track side effec…

This early-phase trial tested a combination of two chemotherapy drugs (gemcitabine and carboplatin) plus lenalidomide, a drug that blocks blood vessel growth in tumors, in 18 adults with advanced solid tumors, especially urothelial (bladder) cancer. The main goal was to find the …

Researchers are testing whether adding brain radiotherapy to PD-1/PD-L1 inhibitors and chemotherapy helps people with untreated stage IV non-small cell lung cancer that has spread to the brain. The trial enrolls about 40 adults whose tumors lack common driver mutations and whose …

This early-phase trial tests a new drug called AI-061, which combines two immune-boosting antibodies (anti-PD-1 and anti-CTLA-4) into one treatment. The study will enroll 18 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to find a safe…

This study tests a new drug, Tuvusertib, combined with an immunotherapy called Cemiplimab in people with a specific type of advanced lung cancer (non-squamous non-small cell) that has worsened after prior treatments. The trial aims to see if the combination can shrink tumors and …

This pilot study tested a new, non-invasive way to locate multiple small lung nodules (under 20 mm) before surgery, comparing it to the standard CT-guided needle method. Forty people with early-stage lung cancer took part. The goal was to see if the new method could help surgeons…

Researchers are testing an experimental drug called MRG003 in adults with EGFR-positive advanced non-small cell lung cancer that has worsened after at least two standard treatments. The trial enrolls about 87 participants across multiple sites and gives MRG003 intravenously as a …

This phase 2 trial tests whether adding an experimental drug called pixatimod to the immunotherapy nivolumab can shrink tumors in people with advanced melanoma, non-small cell lung cancer, or colorectal cancer that has stopped responding to prior treatment. One group with colorec…

This phase 3 trial tested whether a combination of sitravatinib (a targeted drug) and nivolumab (an immunotherapy) works better than docetaxel (standard chemo) for people with advanced non-squamous non-small cell lung cancer that got worse after platinum chemo and checkpoint inhi…

This trial studies people with advanced non-small cell lung cancer who have already tried platinum-based chemotherapy. Researchers compare those who receive immunotherapy with those who receive standard chemotherapy as a second-line treatment. The goal is to see which approach he…

This trial tests an experimental drug called FLX475, given alone or with the immunotherapy pembrolizumab, in people with advanced cancers that have not responded to standard treatments. The study aims to find the safest dose and to see whether the combination can shrink tumors. P…

This trial tests an experimental drug called SNS-101, which targets a protein called VISTA that may help tumors evade the immune system. Researchers give SNS-101 alone or with another immunotherapy, cemiplimab, to adults with advanced solid tumors that have not responded to stand…

This trial tests whether combining the immunotherapy drug atezolizumab with precise, high-dose radiation (SABR) can better control metastatic cancers, including colorectal, lung, kidney, and sarcoma. The idea is that radiation may make tumors more visible to the immune system, wh…

This Phase 2 trial tests a combination of three drugs—amivantamab, lazertinib, and pemetrexed—as a first treatment for people with advanced lung cancer that has a specific EGFR mutation. The study includes 54 participants across Latin America. Researchers want to see if this comb…

This study is monitoring the safety and side effects of the drug XALKORI in people with a certain type of advanced lung cancer (ROS1-positive non-small cell lung cancer) who have not taken this drug before. About 97 participants are being followed to see how well the drug works a…

This phase 3 trial tests whether a new drug combination (MK-7684A) plus chemoradiotherapy helps people with stage III non-small cell lung cancer live longer than the current standard treatment. About 611 participants will receive either the new combo or durvalumab. The study is a…

This early-stage study tests a new drug called WTX-124, given alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 150 adults with certain…

This trial investigates whether combining two targeted drugs—erlotinib and bevacizumab—can help people with advanced non-small cell lung cancer that has specific EGFR mutations. The goal is to see if the combination extends the time before the cancer grows or spreads. Participant…

This phase 2 trial investigates whether afatinib, an oral targeted therapy, can control advanced non-small cell lung cancer (NSCLC) that carries a specific HER2 exon 20 mutation. Participants have already received prior chemotherapy and have stage IIIB or IV disease. The study me…

This trial is testing whether a blood test called VeriStrat can help choose between two drugs for people with advanced squamous non-small cell lung cancer that has progressed after initial chemotherapy. Participants are grouped by their VeriStrat result (good or poor) and then ra…

This study tested whether adding bevacizumab to osimertinib helps people with advanced non-small cell lung cancer that has a specific genetic change (EGFR and T790M mutations). 155 adults who had already tried other treatments took part. The main goal was to see if the combinatio…

This trial is investigating whether adding the immunotherapy drug nivolumab to the usual chemotherapy and radiation can improve outcomes for people with stage III non-small cell lung cancer. The study will measure how well the combination works and how tolerable the side effects …

This phase 2 trial tested a combination of two targeted drugs, tepotinib and osimertinib, in 140 people with advanced non-small cell lung cancer that has a specific genetic change (MET amplification) and had stopped responding to the standard drug osimertinib. The goal was to see…

This early-stage trial is testing an oral drug called LOXO-260 in about 70 people with advanced cancers that have a specific change in the RET gene. The cancers have stopped responding to other targeted treatments. The study aims to find the safest dose and see if the drug can sh…

This study tested an experimental drug called CBX-12 in 69 adults with advanced solid tumors (like ovarian, lung, breast, or colon cancer) that had stopped responding to standard therapies. The main goals were to check the drug's safety, find the best dose, and see if it could sh…

This study tests the safety of combining the targeted drug alectinib with chemotherapy in people who have had surgery for a specific type of lung cancer (ALK-positive non-small cell lung cancer). The 11 participants received up to four cycles of the drug combo after their tumor w…

This trial investigates an experimental oral drug, LY3143921 hydrate, which blocks a protein called Cdc7 that cancer cells need to divide. It is being tested in adults with advanced solid tumours, including colorectal, ovarian, lung, and pancreatic cancers, that have not responde…

This trial is investigating whether adding an experimental antibody called CS1001 to standard chemotherapy can help people with stage IV non-small cell lung cancer. The study compares the combination against chemotherapy alone in patients who have not yet received treatment for a…

This early-phase trial tested the drug everolimus (RAD001) alongside radiation therapy in 26 people with advanced non-small cell lung cancer that could not be surgically removed. The goal was to find a safe dose and check for side effects. Participants received everolimus weekly …

This trial is testing whether giving the immunotherapy drug atezolizumab before surgery can help people with early-stage non-small cell lung cancer. The study includes adults with stage IB to IIIA (non-N2) disease who are eligible for surgery. Participants receive one dose of ate…

This early-phase trial tested whether giving patients their own natural killer (NK) cells, boosted by the drug bortezomib, is safe for treating advanced cancers like leukemia, lung, and pancreatic cancer. Thirty-five adults whose cancers had not responded to standard treatments r…

This phase 2 study tested a combination of three drugs in 46 people with a specific type of lung cancer (EGFR-mutated) that had spread to the lining of the brain and spinal cord (meningeal metastasis). The treatment included a high-dose targeted pill (furmonertinib), an intraveno…

This study tested a new way of giving radiation therapy combined with immunotherapy for people with advanced non-small cell lung cancer that does not have certain genetic mutations. The goal was to see if mixing high-dose and low-dose radiation could help the immune system fight …

This phase II trial is testing whether the immunotherapy drug tislelizumab can help control locally advanced non-small cell lung cancer when given after radiation therapy or sequential chemoradiation. The study enrolls people with stage III lung cancer who cannot tolerate the sta…

This early-phase study tests a new oral drug, furmonertinib, in 30 people with advanced non-small cell lung cancer that has a specific EGFR exon 20 insertion mutation. Some participants have already tried other treatments, while others are newly diagnosed. The goal is to see if t…

This Phase 2 trial tests whether adding chemotherapy (carboplatin and pemetrexed) to the targeted drug osimertinib works better than osimertinib alone for people with a specific type of advanced lung cancer (EGFR-mutant non-small cell lung cancer). The study enrolls 80 patients w…

This early-stage trial is testing whether an immunotherapy drug called tislelizumab can be given as a simple injection under the skin instead of through an IV drip for people with advanced non-small cell lung cancer. The study will compare how well the body absorbs the drug in bo…

This early-phase study tested a new drug called BAY 2862789 in 45 people with advanced solid tumors, including non-small cell lung cancer. The drug works by activating immune cells to fight cancer. The main goals were to check safety, find the best dose, and see how the drug move…

This trial is testing a new radiation technique called CT-STAR for people with early-stage non-small cell lung cancer located near the center of the chest, where treatment is tricky. The approach uses a machine that takes CT images during each session and adapts the radiation pla…

This trial is testing whether adding the immunotherapy drug toripalimab to standard chemotherapy can help people with advanced non-small cell lung cancer whose tumors have a specific EGFR mutation and have stopped responding to TKI targeted therapy. About 440 participants will be…

This trial is testing whether adding the traditional herbal remedy Bojungikki-tang to the immunotherapy drug pembrolizumab can help people with advanced non-small cell lung cancer. The study includes adults with stage IV disease whose tumors are PD-L1 positive and who have no EGF…

This study tests whether adding thymosin alpha 1 to standard chemoradiation and immunotherapy helps patients with advanced non-small cell lung cancer complete a full year of immunotherapy. About 114 adults will participate. The goal is to see if this approach improves survival an…

This completed Phase 1/2 trial tested a combination of two drugs, amivantamab and docetaxel, in 12 people with advanced non-small cell lung cancer that had spread. The goal was to find a safe dose and see if the combo could shrink tumors. The study focused on patients whose cance…

This trial is testing whether adding an experimental drug called HBI-8000 to the immunotherapy nivolumab can safely control advanced melanoma, kidney cancer, and non-small cell lung cancer. The study enrolls adults whose cancers have not responded to prior treatments. Researchers…

This early-phase trial is testing an experimental drug called SPYK04 in people with advanced solid tumors that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look for early signs that SPYK…

This study tested a new drug combination for people with a specific type of advanced lung cancer (EGFR-mutant non-small cell) that had stopped responding to standard targeted pills. The trial enrolled 95 adults and gave them two different combinations of immunotherapy (atezolizum…

This phase 2 trial tests whether adding lenvatinib to a standard chemotherapy-plus-immunotherapy regimen can shrink tumors in people with advanced non-squamous non-small cell lung cancer that has a specific EGFR mutation. Participants will receive lenvatinib capsules daily along …

This study tested the drug osimertinib (Tagrisso) in 73 patients with a specific type of lung cancer that had spread to the lining of the brain and spinal cord (leptomeningeal metastases). Patients took one 80 mg tablet daily. The goal was to see if the drug could improve overall…

This study tested a combination of two immunotherapy drugs (durvalumab and tremelimumab) plus a targeted therapy (selumetinib) in 40 people with advanced non-small cell lung cancer that had returned or spread. The goal was to find the safest dose and see if the combo could shrink…

This trial tests an experimental drug, RSO-021, given directly into the chest cavity of people with malignant pleural effusion—a buildup of fluid around the lungs caused by advanced solid tumors or mesothelioma. The study aims to find a safe dose and check for early signs that th…

This phase 3 trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy before surgery can improve outcomes for people with stage II-III non-small cell lung cancer. Participants receive either toripalimab plus chemotherapy or a placebo plus chemotherap…

This phase 3 trial compares the experimental drug AMG 510 (sotorasib) to the standard chemotherapy docetaxel in people with advanced non-small cell lung cancer that has a specific mutation called KRAS G12C. About 345 participants who have already received prior treatment are bein…

This phase II trial is testing whether adding the immunotherapy drug atezolizumab to standard chemotherapy and radiation can help people with stage III non-small cell lung cancer that cannot be surgically removed. About 50 participants will receive the combination treatment, and …

This study tested whether adding a bronchoscopy-guided treatment to standard immunotherapy and chemotherapy could help people with advanced central non-small cell lung cancer. The trial included 33 adults whose cancer could not be surgically removed. The goal was to see if the tr…

This early-phase trial is testing a combination of all-trans retinoic acid (ATRA), a substance made from vitamin A, and the immunotherapy drug atezolizumab in people with advanced non-small cell lung cancer that has spread or come back. The main goal is to find the safest dose an…

This study compares a new drug, tobemstomig, combined with chemotherapy against the current standard treatment (pembrolizumab plus chemo) for people with advanced non-small cell lung cancer that has not been treated before. The goal is to see if the new combination works better a…

This trial investigates whether combining stereotactic body radiotherapy (SBRT), a precise form of radiation, with the immunotherapy drug nivolumab is safe and tolerable for people with early-stage non-small cell lung cancer. Participants receive SBRT followed by nivolumab infusi…

This trial tests an experimental drug called enfortumab vedotin, which is designed to seek out and destroy cancer cells that have a specific protein called Nectin-4 on their surface. The study includes people with metastatic urothelial cancer (a type of bladder cancer) and other …

This study is monitoring the safety and effectiveness of the drug brigatinib in adults with a specific type of advanced lung cancer (ALK-positive NSCLC) in South Korea. Researchers will track side effects and how well the drug controls the cancer in 257 patients who are starting …

This early-phase trial tested a new drug called CHS-388 in 145 people with advanced solid tumors (kidney, liver, or lung cancer) that had stopped responding to standard treatments. CHS-388 is an antibody that blocks a protein called IL-27, which may help the immune system fight c…

This phase 3 trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy and radiation can help people with stage III lung cancer that cannot be removed by surgery. About 328 participants will receive either durvalumab or a placebo alongside their chemo …

This phase 2 trial tests the experimental drug LDK378 in adults with advanced non-small cell lung cancer that has a specific genetic change called a ROS1 rearrangement. Participants must have already received at least one platinum-based chemotherapy and their cancer must have pro…

This study reviews medical records of 35 adults with a specific lung cancer (ROS1-positive NSCLC) that had not been controlled by other treatments. All participants took lorlatinib pills at home until their cancer stopped responding. Researchers will analyze how long the drug kep…

This study tests a new drug called pegilodecakin, a lab-made version of a natural immune protein (interleukin-10), in people with advanced solid tumors such as melanoma, lung, breast, prostate, ovarian, kidney, colorectal, and pancreatic cancers. The drug is given as a daily shot…

This phase II trial tests whether adding canakinumab, an anti-inflammatory drug, to standard chemoradiation and immunotherapy (durvalumab) helps control locally advanced non-small cell lung cancer. About 41 participants will receive the combination to see if it improves progressi…

This early-phase study tests a new oral drug called TT125-802 in 50 adults with advanced solid tumors (like lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. It is a fi…

This study tested whether combining two drugs, brentuximab vedotin and pembrolizumab, can shrink tumors in people with advanced melanoma, lung cancer, or head and neck cancer that has spread. About 161 adults took part. The main goal was to see how many patients had their tumors …

This study investigates whether 4DCT scans—which capture how a tumor moves when a person breathes—can be used to design radiation plans that avoid high-functioning healthy lung tissue. People with non-small cell lung cancer who are scheduled for radiation therapy may join. The go…

This phase 3 trial tested whether adding the drug olaparib (Lynparza) to standard treatment with pembrolizumab (Keytruda) and chemotherapy helps people with advanced nonsquamous lung cancer live longer without their disease worsening. Over 1,000 participants received either olapa…

This phase 3 study tested whether adding the immunotherapy drug retifanlimab (INCMGA00012) to standard platinum-based chemotherapy helps people with advanced non-small cell lung cancer live longer. The trial enrolled 583 patients who had not received prior treatment for metastati…

This study tests a device called the LungVision system, which uses artificial intelligence to help surgeons locate small lung nodules during minimally invasive surgery. The system combines CT scans with live X-ray images to guide a tool to the nodule, then injects a dye to mark i…

This study tests whether combining two targeted drugs, avutometinib and adagrasib, can shrink tumors in people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. Participants must have already tried a KRAS G12C inhibitor and seen their c…

This trial tests whether a gentler suction level (-2 cmH2O) on chest tubes after keyhole lung cancer surgery works as well as the standard stronger suction (-10 cmH2O). The goal is to see which setting allows tubes to be removed sooner and causes fewer complications. About 230 ad…

This study tested the drug larotrectinib in 215 adults with various solid cancers that have a specific change in the NTRK gene. The drug is taken orally and works by blocking the action of the altered gene. The main goal was to see how many patients had their tumors shrink or dis…

This phase II trial tests whether a low-dose, frequent schedule of the chemotherapy drug vinorelbine, taken orally, can boost the effects of the immunotherapy atezolizumab in people with stage IV non-small cell lung cancer. The study enrolls adults whose cancer has progressed aft…

This Phase 3 trial tested a new targeted therapy, lazertinib, against the standard drug gefitinib in 393 people with advanced EGFR-mutated non-small cell lung cancer. The goal was to see if lazertinib could keep cancer from growing longer. Participants took either lazertinib or g…

This study tested whether adding another drug to the immunotherapy pembrolizumab (Keytruda) can help people with advanced non-small cell lung cancer whose disease got worse after initial treatment. 128 participants received one of three drug combinations. The goal was to see if t…

This phase 3 trial tested alectinib against crizotinib in 187 Asian patients with advanced ALK-positive non-small cell lung cancer who had not received prior treatment. Patients took either alectinib or crizotinib capsules twice daily. The study found that alectinib significantly…

This large phase III trial tested whether adding bevacizumab (Avastin) to standard chemotherapy after complete lung cancer surgery could help patients live longer. Over 1,500 patients with stage IB to IIIA non-small cell lung cancer took part. The study found that adding bevacizu…

This study tested whether adding veliparib (a PARP inhibitor) to standard chemotherapy (cisplatin and etoposide) helps people with extensive stage small cell lung cancer or certain other lung cancers that have spread. In the first phase, researchers found the best dose of velipar…

This phase 2 trial tests the drug crizotinib (XALKORI) in people with advanced non-small cell lung cancer that has spread and carries a change in the ROS1 or MET gene. Participants take crizotinib by mouth twice daily. The study aims to see how well the drug shrinks tumors and de…

This phase III trial investigates whether sunitinib, a drug that blocks tumor blood vessel growth, can help patients with advanced non-small cell lung cancer maintain their response after initial chemotherapy. Participants who did not worsen after four cycles of platinum-based ch…

This phase 3 trial tested the immunotherapy drug cemiplimab against standard platinum-based chemotherapy in 712 patients with advanced or metastatic non-small cell lung cancer that has high PD-L1 levels. The study aimed to see if cemiplimab improves overall survival and delays ca…

This large phase 3 trial tested whether the immunotherapy drug pembrolizumab (Keytruda) could help people with a specific type of advanced lung cancer live longer than standard chemotherapy. Over 1,200 participants with PD-L1 positive non-small cell lung cancer were randomly assi…

This phase 2 trial is testing the targeted drug brigatinib in 118 people with ALK-positive non-small cell lung cancer that has spread or cannot be surgically removed. The main goal is to see how long the cancer stays under control before it progresses. Researchers are also studyi…

This phase 3 trial tested whether adding niraparib (a drug that interferes with cancer cell repair) to pembrolizumab (an immunotherapy) helps keep advanced non-small cell lung cancer from progressing. The study enrolled 666 adults whose cancer had stabilized or shrunk after initi…

This early-phase trial tested a new drug called RO7496353 combined with an immunotherapy (atezolizumab) and sometimes chemotherapy in 102 people with advanced lung, stomach, or pancreatic cancer. The main goal was to check safety and side effects. Researchers also looked at how t…

This study tested a drug called PF-06801591 in 155 people with advanced solid tumors or non-small-cell lung cancer. The drug works by blocking a protein that stops the immune system from attacking cancer cells. The goal was to check safety, how the drug moves through the body, an…

This phase 2 study tested three different drug combinations in 151 people with advanced non-small cell lung cancer that had not been treated before. The drugs help the immune system attack cancer cells. Researchers measured how many patients' tumors shrank or stopped growing, and…

This study offers ongoing treatment with alectinib or crizotinib to about 200 adults with ALK- or RET-positive cancer who were already benefiting from these drugs in a previous Roche trial. The main goal is to monitor safety and side effects as patients continue therapy after the…

This phase II trial tested a new drug called AK104 (a bispecific antibody that targets two immune checkpoints) combined with the chemotherapy docetaxel in 44 adults with advanced non-small cell lung cancer whose disease had progressed after platinum-based chemotherapy and an anti…

This study tested the safety and effectiveness of Vizimpro (dacomitinib) in 40 Japanese patients with EGFR-mutated non-small cell lung cancer that could not be surgically removed or had returned. Researchers tracked side effects, especially interstitial lung disease, and measured…

This study tested giving immunotherapy drugs (nivolumab alone or with relatlimab) for four weeks before surgery in 90 people with early-stage non-small cell lung cancer. The goal was to see if this approach is feasible and helps shrink tumors before removal. Results help determin…

This study tested whether matching drug combinations to specific biomarkers in advanced non-small cell lung cancer could improve response. 245 patients who had not received prior treatment were grouped by two biomarkers (GEP and TMB) and given pembrolizumab plus another drug. The…

This early-phase study tested a personalized cancer vaccine (RO7198457) in 273 patients with advanced solid tumors like melanoma, lung, and breast cancer. The vaccine was given alone or with an immunotherapy drug (atezolizumab) to see if it was safe and how the body responded. Th…

This early-phase study tested a combination of two drugs, bexarotene and Iressa, in 6 people with advanced non-small cell lung cancer who had already tried standard treatments. The goal was to see if the combination was safe and could help control the disease. The study looked at…

This study tested an oral drug called PLB1001 in 145 people with advanced non-small cell lung cancer whose tumors have a specific genetic change (c-Met dysregulation). The main goal was to see how many patients' tumors shrank or disappeared. The drug is taken twice daily and aims…

This study tested whether adding the experimental immunotherapy tiragolumab to a standard combination of atezolizumab and chemotherapy works better than the current standard treatment (pembrolizumab plus chemotherapy) for people with advanced non-squamous non-small cell lung canc…

This study looked at whether giving immunochemotherapy in the morning or afternoon affects how long people with advanced non-small cell lung cancer live without their disease getting worse. 210 patients were randomly assigned to receive treatment before or after 3 PM. The goal is…

This phase 3 trial tested whether combining two immunotherapy drugs, atezolizumab and tiragolumab, works better than the standard drug durvalumab for people with stage III lung cancer that cannot be surgically removed. The 829 participants had already received chemotherapy and ra…

This phase 2 trial tested two drugs, osimertinib and gefitinib, in 156 people with advanced EGFR-mutant lung cancer. The goal was to see if using blood tests (liquid biopsies) to detect genetic changes could help decide when to switch treatments, compared to standard scans. The s…

This early-stage trial tested a new drug called PF-07257876 in 29 people with advanced lung, head/neck, or ovarian cancers that had stopped responding to other treatments. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals wer…

This completed study looked at how patients with advanced EGFR-positive non-small cell lung cancer fared while taking dacomitinib in real-world settings in Taiwan. Researchers tracked 29 adults who took dacomitinib pills at home until their cancer stopped responding. The goal was…

This phase 3 study tested alectinib against crizotinib in 303 people with advanced ALK-positive non-small cell lung cancer who had not received prior treatment. Participants took one of the two drugs twice daily until their cancer worsened or side effects became too severe. The m…

This phase 2 study tested a combination of two drugs—KN046 (an immunotherapy) and axitinib (a targeted therapy)—in 95 people with advanced non-small cell lung cancer that had not been treated before. The goal was to see if the combo could shrink tumors and how safe it was. The tr…

This study tested a new drug called XTX202 in 95 people with advanced solid tumors that had not responded to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The trial is now complete.

This study tested whether combining two targeted drugs, savolitinib and osimertinib, works better than standard chemotherapy for people with advanced non-small cell lung cancer that has a specific genetic change (MET amplification) and has stopped responding to initial treatment.…

This study tested whether adding an experimental drug (CCR2/5-inhibitor or anti-IL-8) to the immunotherapy nivolumab before and after surgery could help shrink tumors and improve long-term survival in people with non-small cell lung cancer or liver cancer. 48 participants receive…

This phase 3 trial tested whether adding plinabulin to the chemotherapy drug docetaxel helps people with advanced non-small cell lung cancer live longer. 559 participants who had already tried one or two prior treatments received either the combination or docetaxel alone. The stu…

This study tested whether adding the immunotherapy drug camrelizumab to standard chemotherapy and radiation helps people with advanced lung cancer whose disease has spread to the brain. The trial included 60 patients who had not received chemotherapy before. Researchers measured …

This study tested whether adding cetuximab (an antibody) to afatinib (a targeted pill) helps people with advanced EGFR-mutant lung cancer live longer. 174 patients were randomly assigned to receive either the combination or afatinib alone. The results showed no significant improv…

This phase 3 study tested whether adding the immunotherapy drug cemiplimab to standard chemotherapy helps people with advanced non-small cell lung cancer live longer. The trial enrolled 789 participants and compared different drug combinations. The main goal was to see if the com…

This study tested whether combining the immunotherapy drug pembrolizumab (Keytruda) with precise radiation therapy could help people with advanced non-small cell lung cancer. The trial enrolled 124 participants with stage IV disease. The goal was to see if the combination could s…

This phase 2 study tested whether adding the targeted drug erlotinib to standard chemotherapy (docetaxel) works better than chemotherapy alone for people with advanced non-small cell lung cancer whose first treatment stopped working. 156 participants were randomly assigned to one…

This study tested a new drug (ningetinib) combined with an existing targeted therapy (gefitinib) in 108 people with advanced lung cancer whose cancer had stopped responding to previous treatments. The goal was to find the safest dose and see if the combination could shrink tumors…

This phase 3 study tested whether adding the immunotherapy drug sintilimab to standard chemotherapy helps people with advanced non-squamous non-small cell lung cancer. 397 participants received either sintilimab plus chemo or a placebo plus chemo. The main goal was to see if the …

This phase 2 trial tested a combination of chemotherapy (carboplatin or cisplatin plus pemetrexed) and immunotherapy (atezolizumab, with or without bevacizumab) in 150 people with advanced non-squamous non-small cell lung cancer that has EGFR, ALK, or ROS1 mutations and has progr…

This early-stage study tested a custom-made yeast vaccine designed to train the immune system to recognize and attack leftover cancer cells. Five adults with various cancers (like colorectal, breast, or lung) who had completed initial treatment received the vaccine. The goal was …

This phase 2 trial tested a drug called patritumab deruxtecan (HER3-DXd) in 63 patients with breast cancer, lung cancer, or other solid tumors that had spread to the brain or the lining of the brain and spinal cord. The drug is designed to seek out and destroy cancer cells carryi…

This phase 2 study tested whether adding tiragolumab to the standard immunotherapy atezolizumab helps people with advanced non-small cell lung cancer who have not had chemotherapy. 135 participants received either the combination or a placebo plus atezolizumab. The main goals wer…

This study tested a new way to deliver high-dose radiation to small lung tumors in just one day, instead of the usual two to three weeks. Ten patients with early-stage lung cancer or limited lung metastases received a single session of stereotactic body radiotherapy (SBRT) using …

This study tested a new oral drug called ensartinib (X-396) for the first time in humans. It involved 131 people with advanced solid tumors, including those with ALK-positive non-small cell lung cancer. The goal was to find the safest dose and see if the drug could shrink tumors.…

This phase 2 trial tested a combination of FLT3 ligand immunotherapy (CDX-301) and stereotactic body radiotherapy (SBRT) in 33 adults with advanced non-small cell lung cancer that had worsened after standard treatments. The goal was to see if this approach could slow cancer growt…

This study tested whether customizing chemotherapy based on specific gene mutations (EGFR and BRCA1) could improve outcomes for 153 patients with advanced lung adenocarcinoma. Participants received treatments matched to their tumor's genetic profile. The goal was to see if this p…

This trial tested several targeted drugs in people with non-small cell lung cancer whose tumors had specific genetic changes. The goal was to see if these drugs could shrink tumors or delay cancer growth. Over 400 participants received treatment based on their tumor's genetic pro…

This study tested a new targeted therapy, AZD9291 (osimertinib), against the usual targeted drugs for people with a specific genetic mutation (EGFR) in advanced non-small cell lung cancer. Over 600 participants received either the new drug or standard care. The main goal was to s…

This study tested whether adding a precise, high-dose radiation treatment called CyberKnife after standard chemo and radiation could help people with stage III non-small cell lung cancer. It included 35 patients who had 1 to 3 small tumors left after initial treatment. The goal w…

This phase 2 study tested a combination of four drugs—atezolizumab, bevacizumab, a platinum drug, and pemetrexed—in 22 people with advanced EGFR-mutant non-small cell lung cancer whose disease had progressed after EGFR-targeted therapy. The goal was to see how many patients' tumo…

This study tested a new two-drug combination (anvumetostat and IDE397) in 53 adults with advanced solid tumors that lack a gene called MTAP. The goal was to find a safe dose and see if the drugs shrink tumors, especially in lung cancer. Participants had cancers that had stopped r…

This early-phase study tested whether combining the immunotherapy drug pembrolizumab with standard palliative radiation is safe for people with advanced lung cancer. Twenty-four participants received different doses of pembrolizumab alongside radiation, then continued pembrolizum…

This study tested a combination of two immunotherapy drugs (eftilagimod alpha and pembrolizumab) in 187 people with advanced lung cancer or head/neck cancer that had not been treated or had stopped responding to prior therapy. The goal was to see if the combination could shrink t…

This study tested whether using PET/CT scans during treatment to adjust radiation plans can improve outcomes for people with stage III non-small cell lung cancer. 138 participants were randomly assigned to receive either standard radiation or radiation guided by mid-treatment sca…

This phase 2 trial tested a combination of two drugs, tucidinostat and tislelizumab, as a first treatment for people with a type of advanced lung cancer that has a specific marker (PD-L1 positive). The study involved 118 participants and aimed to see if the combo could delay canc…

This study tested a new drug called AZD9291 in 603 people with advanced non-small cell lung cancer whose tumors had started growing again after previous targeted therapy. The main goals were to find the safest and most effective dose, measure how the drug moves through the body, …

This early-stage trial tested an experimental drug called CTX-471, given alone or with the approved drug Keytruda, in 100 adults with advanced cancers like lung cancer, melanoma, and head and neck cancer. The goal was to see if the combination is safe and tolerable for patients w…

This Phase 3 trial tested whether adding custirsen to the chemotherapy drug docetaxel helps people with advanced non-small cell lung cancer live longer. The study involved 664 patients who had already tried one platinum-based treatment. Researchers compared survival between those…

This study tested whether giving the drug durvalumab after precise radiation therapy (SBRT) helps people with early-stage lung cancer stay cancer-free longer. About 106 patients with stage I non-small cell lung cancer who could not have surgery or chose not to were randomly assig…

This early-phase trial tested two experimental drug combinations in 37 people with advanced EGFR-mutant lung cancer that no longer responded to the targeted therapy osimertinib. The goal was to find safe, tolerable doses of alisertib or sapanisertib when given together with osime…

This early-phase trial tested the drug cilengitide given continuously along with standard chemotherapy and radiation in 14 patients with locally advanced non-small cell lung cancer. The main goal was to find the highest safe dose of cilengitide when used this way. Researchers als…

This study tracked 296 patients with advanced or recurrent non-small cell lung cancer who received a combination of IMJUDO, IMFINZI, and platinum-based chemotherapy. The goal was to see how safe the treatment is in everyday medical practice. Researchers recorded any side effects …

This phase 3 trial tested GME751, a biosimilar (copy) of the immunotherapy drug Keytruda, against the original Keytruda in 218 adults with untreated advanced non-squamous lung cancer. The goal was to see if GME751 works as well and is as safe as Keytruda when combined with chemot…

This phase 2 trial tested a new cancer vaccine (IO102-IO103) combined with the immunotherapy drug pembrolizumab as a first treatment for people with advanced lung, head/neck, or bladder cancer that had spread. The study enrolled 63 participants to see if the combination is safe a…

This early-phase trial tested the safety of combining two drugs—L-NMMA and pembrolizumab (Keytruda)—in 12 adults with various advanced cancers. Pembrolizumab helps the immune system recognize cancer cells, while L-NMMA may remove a chemical barrier that blocks immune attack. The …

This phase 2 trial tested a combination of the immunotherapy drug pembrolizumab and a personalized 4-week course of radiotherapy in 25 patients with advanced non-small cell lung cancer whose tumors had high PD-L1 levels. The goal was to see if this approach could control the canc…

This completed study looked at how safe sotorasib is for Chinese patients with a certain type of advanced lung cancer (KRAS G12C-mutated NSCLC). 102 patients who had already tried other treatments took sotorasib pills daily. Researchers tracked side effects and how long patients …

This study tested the drug durvalumab in 446 people with advanced non-small cell lung cancer who had already tried at least two prior treatments. The goal was to see if the drug could shrink tumors or slow the disease. Participants received infusions every two weeks for up to 12 …

This study tested a drug called capmatinib in 50 Indian adults with advanced non-small cell lung cancer that has a specific genetic change (MET exon 14 skipping mutation). The goal was to see how safe the drug is and how well it shrinks tumors. Participants took capmatinib pills,…

This study tested giving immunotherapy drugs (nivolumab alone or with ipilimumab) or immunotherapy plus chemotherapy before surgery for people with early-stage non-small cell lung cancer (stages I to IIIA). The goal was to see if these treatments could shrink or eliminate the tum…

This study tested a new drug called STRO-002 in 19 Chinese adults with advanced ovarian, endometrial, or other solid tumors that had not responded to prior treatments. STRO-002 is an antibody-drug conjugate, meaning it combines a targeted antibody with a chemotherapy drug to deli…

This study tested an experimental drug called BMS-986016 (anti-LAG-3) alone or combined with nivolumab in people with advanced solid tumors that had spread or couldn't be removed by surgery. It included several cancer types like lung, stomach, liver, kidney, bladder, head and nec…

This study tested combinations of three immunotherapy drugs—tislelizumab, surzebiclimab, and alcestobart—in 147 adults with advanced solid tumors that had not responded to prior treatments. The goal was to find safe doses and see if the drugs could shrink tumors. The trial is now…

This study tested a combination of an immune-boosting drug (durvalumab) and a precise, high-dose radiation treatment (SBRT) for people with stage III lung cancer that hadn't spread. The goal was to see if adding SBRT after standard chemoradiation could help control the cancer lon…

This early-phase trial tested an experimental drug called BAT8010 in 23 people with advanced or metastatic solid tumors who had no other standard treatment options. The main goals were to check safety, find the best dose, and see if the drug shows any sign of shrinking tumors. Pa…

This study tested an oral targeted drug called capmatinib in 36 Chinese adults with advanced non-small cell lung cancer that has a specific MET gene mutation (exon 14 skipping). The drug aims to block faulty signals that help cancer grow. Researchers measured how many patients' t…

This study tested a new cancer drug called brigimadlin (BI 907828) in 266 adults with advanced solid tumors that had spread or stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. Brigimadlin is an MDM2 inhibitor tak…

This early-phase study tested a personalized immunotherapy (iNeo-Vac-P01) in 6 patients with stage III colorectal or non-small cell lung cancer who had already completed surgery and standard adjuvant therapy. The vaccine was designed to target unique neoantigens from each patient…

This small, completed study tested whether it is possible to personalize radiation doses for people with stage II or III non-small cell lung cancer based on the genetic profile of their tumor. Three participants received either standard or higher radiation doses depending on a ra…

This phase II trial tested a combination of thoracic radiotherapy and the immunotherapy drug durvalumab in 51 elderly or frail patients with stage III lung cancer who could not receive chemotherapy. The goal was to see if this approach is safe and can shrink tumors. The study foc…

This early-phase trial tested a light-measuring system used during photodynamic therapy (PDT) for people with malignant mesothelioma, non-small cell lung cancer, or other pleural cancers. Nine participants received the drug porfimer sodium, which becomes active when exposed to li…

This study tested a combination of two targeted drugs, encorafenib and binimetinib, in 98 people with advanced non-small cell lung cancer that has a specific BRAF gene mutation. The goal was to see if the drugs could shrink tumors and how safe they were. Participants had either n…

This phase 2 trial tested the drug DS-1062a in 137 adults with advanced or metastatic non-small cell lung cancer that has specific genetic changes and has worsened after targeted therapy and chemotherapy. The main goal was to see how many patients' tumors shrank or disappeared. T…

This phase 3 trial tested a portable device that creates electric fields to disrupt cancer cell division in 291 people with stage 4 non-small cell lung cancer that had worsened after initial chemotherapy. Participants wore the device on their chest while continuing standard treat…

This early-stage study tested a new drug called DF6215, alone or with another drug (pembrolizumab), in 35 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find the safest dose and check for side effects. The study is com…

This study tested the immunotherapy drug pembrolizumab in 35 people with early-stage non-small cell lung cancer. Participants received the drug before and after surgery to see if it could help the immune system attack cancer cells. The main goal was to check if surgery could stil…

This early-phase trial tested an experimental drug called DF6002, either alone or combined with the approved immunotherapy nivolumab (Opdivo), in 170 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find th…

This phase 3 trial tested the drug pembrolizumab (Keytruda) against a placebo in 1,177 people with early-stage non-small cell lung cancer who had already had surgery. The goal was to see if pembrolizumab could delay the cancer from coming back. Participants received either the dr…

This study tested a new drug called DF1001 in 270 adults with advanced solid tumors that have spread or cannot be removed. The drug works by helping the body's immune cells attack cancer cells. The trial first found the safest dose, then tested it alone or with other cancer drugs…

This study tested whether a short course of radiation to one tumor site could help immunotherapy drugs work better in people with advanced lung or head/neck cancers. 76 participants received radiation within two weeks of starting their immunotherapy. The main goal was to see if t…

This early-phase study tested a new drug called ONO-7475 combined with the standard targeted therapy osimertinib in 78 people with advanced EGFR-mutated non-small cell lung cancer. The goal was to see if the combination is safe and tolerable. Participants had stage IIIB, IIIC, IV…

This Phase 3 study tested whether adding bevacizumab (Avastin) to erlotinib (Tarceva) works better than erlotinib alone for Chinese patients with advanced non-small cell lung cancer (NSCLC) that has specific EGFR mutations. Over 300 patients were randomly assigned to one of the t…

This study tested a drug called daratumumab in 8 people with a specific genetic mutation (STK11/LKB1) in advanced non-small cell lung cancer who had already tried other treatments. The goal was to see if the drug could shrink tumors. The study was small and designed to find early…

This study tested a combination of two drugs—NT-I7 (efineptakin alfa) and pembrolizumab (Keytruda)—in 215 people with advanced solid tumors that had stopped responding to treatment. The goal was to check safety, find the right dose, and see if the combo could shrink tumors. The t…

This study looked at how well the drug lorlatinib works for people with advanced non-small cell lung cancer that has a specific gene change (ALK). All 73 participants had already tried other treatments and took lorlatinib pills at home. The study tracked how long the drug kept th…

This early study tested combining the immunotherapy drug pembrolizumab with precise radiation (stereotactic radiosurgery) in 25 people with melanoma or lung cancer that had spread to the brain. The main goal was to check for serious side effects. Researchers also tracked how long…

This study tested a combination of two experimental drugs, AK112 and AK117, with or without chemotherapy, in 154 people with advanced solid tumors. The goal was to see if the combo could shrink tumors and control the disease. The trial has finished, and researchers are now lookin…

This trial tested a new drug called AK112 in 108 people with advanced non-small cell lung cancer. The drug targets both PD-1 and VEGF to attack cancer cells and cut off their blood supply. The study aimed to see if the drug shrinks tumors and how safe it is. Participants had stag…

This study tested a combination of two drugs, SHR-1210 (given through a vein) and Apatinib (a daily pill), in 210 adults with advanced non-small cell lung cancer that had stopped responding to standard chemotherapy. The goal was to see if the combo could shrink tumors and to chec…

This study tested a combination of two drugs—bevacizumab and a higher dose of icotinib—in 35 people with advanced non-squamous lung cancer that has a specific genetic change (EGFR L858R). The goal was to see if this combo could delay cancer growth better than standard treatment. …

This study tested a combination of two drugs—nivolumab (Opdivo) and ALT-803—in 67 people with advanced non-small cell lung cancer that had not responded to prior treatments. The goal was to find a safe dose and see if the combination could shrink tumors. The trial is now complete…

This phase 3 trial tested whether adding lenvatinib to pembrolizumab helps people with untreated advanced non-small cell lung cancer whose tumors have PD-L1 levels of 1% or higher. Over 600 participants received either the combination or pembrolizumab alone. The study measured ho…

This early-phase trial tested two oral drugs, palbociclib and binimetinib, in 34 people with advanced lung cancer that has a specific change in the KRAS gene. The goal was to find the safest dose and see if the combination can slow cancer growth. The study is complete, but result…

This study tested whether adding itacitinib to the standard drug osimertinib is safe and effective for people with advanced non-small cell lung cancer that has a specific EGFR gene mutation. The trial involved 59 participants and was completed. The goal was to see if the combinat…

This study tested giving the immunotherapy drug tislelizumab, alone or with other drugs, before surgery for people with stage II to IIIA non-small cell lung cancer that could be removed. The goal was to see if this approach could shrink tumors and improve outcomes. 121 adults too…

This phase 3 trial tested whether adding the targeted therapy lenvatinib to a standard combination of immunotherapy (pembrolizumab) and chemotherapy could help people with a common type of advanced lung cancer live longer. The study enrolled 761 adults with metastatic nonsquamous…

This early-phase trial tested whether injecting the chemotherapy drug cisplatin directly into lung tumors (during a bronchoscopy) is safe for people with early-stage, resectable non-small cell lung cancer. Only 6 participants were enrolled, and the main goal was to find the highe…

This study tested whether a procedure called local ablative therapy (LAT) can help control metastatic non-small cell lung cancer (NSCLC) when a blood test shows signs of remaining cancer (minimal residual disease, or MRD). 37 patients with stage IV NSCLC received LAT to all visib…

This study tested whether adding aspirin to the targeted drug osimertinib helps control advanced EGFR-positive non-small cell lung cancer. 216 participants received the combination as their first treatment. The goal was to see if it delays cancer progression and improves survival…

This early-phase study tests two experimental drugs, BI 765049 and ezabenlimab, in adults with advanced solid tumors like colorectal, lung, and pancreatic cancer. The main goal is to find the highest safe dose of BI 765049 alone and in combination with ezabenlimab. Participants r…

This study tested whether adding a new drug called tiragolumab to the standard immunotherapy atezolizumab works better than atezolizumab alone for people with advanced non-small cell lung cancer that has not been treated before. About 620 participants with high levels of a protei…

This early-phase trial tested adding the anti-parasitic drug atovaquone to standard chemotherapy and radiation for people with locally advanced non-small cell lung cancer. The main goal was to find the safest dose of atovaquone in this combination. Twenty-one participants receive…

This study tested two experimental drugs (BI 754111 and BI 754091) that help the immune system attack cancer. It included 172 adults with advanced solid tumors, including non-small cell lung cancer that had returned after prior treatment. The first part found the safest dose, and…

This study tested whether adding a new drug (LY2875358) to the standard treatment erlotinib helps people with advanced non-small cell lung cancer that has a specific gene mutation. All 168 participants first took erlotinib alone for 8 weeks. Those whose cancer did not worsen were…

This study tested a combination of two drugs—pembrolizumab (Keytruda) and Imprime PGG—in 35 people with advanced non-small cell lung cancer whose disease had worsened after initial treatment. The goal was to find a safe dose and see if the combination could slow cancer growth. Th…

This study tested a powered stapler used during lung cancer surgery in 61 patients. The goal was to see if the device was safe and worked well. Researchers checked for leaks and other complications. The study is complete, but results are not yet published.

This study tested whether adding two immunotherapy drugs (nivolumab and ipilimumab) after standard chemoradiation could better control stage III lung cancer compared to nivolumab alone. 105 patients were randomly assigned to one of the two treatment groups. The main goal was to s…

This study tested whether adding the immunotherapy drug atezolizumab to standard chemotherapy before surgery helps people with stage II to IIIB non-small cell lung cancer live longer without the cancer coming back. About 453 participants received either atezolizumab plus chemo or…

This early-phase trial tested a combination of two drugs—pembrolizumab (an immunotherapy) and nintedanib (a drug that blocks blood vessel growth)—in 196 adults with advanced solid tumors that had worsened after standard treatment. The main goal was to find the safest dose of nint…

This early-phase trial tested a new oral drug called JAB-21822, alone or with cetuximab, in 29 adults with advanced solid tumors (like lung or colorectal cancer) that have a specific KRAS G12C mutation. The main goals were to check safety and find the right dose. Participants had…

This study tested a drug called cabozantinib, either alone or with another drug (erlotinib), in 92 people with advanced non-small cell lung cancer whose cancer had worsened after erlotinib treatment. The goal was to find a safe dose and see if the combination could shrink tumors.…

This study tested a combination of two targeted drugs, dabrafenib and trametinib, in 40 Chinese adults with a specific type of advanced lung cancer (BRAF V600E mutation-positive NSCLC). The goal was to see if the drugs could shrink tumors and control the cancer. Participants rece…

This study tested a daily pill called AZD9291 in 171 people from Asia Pacific with advanced lung cancer that has a specific genetic change (T790M mutation). The goal was to see if the drug could shrink tumors and control the disease after other treatments stopped working. Researc…

This phase 2 trial tested a new drug called gimistotug (BGB-A445) combined with either another experimental drug (BGB-15025) or the standard chemo docetaxel in 35 people with advanced non-small cell lung cancer. All participants had already tried an immunotherapy and chemotherapy…

This phase 2 trial tested a combination of two oral drugs, RMC-4630 and sotorasib, in 47 adults with advanced KRASG12C-mutant non-small cell lung cancer that had progressed after standard treatments. The goal was to see if the combination could shrink tumors. The study is now com…

This early-phase study tested a combination of two experimental drugs (BGB-283 and PD-0325901) in 91 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if the drugs could shrink tumors. The trial is no…

This phase 3 trial tested whether adding the immunotherapy drugs nivolumab (Opdivo) and ipilimumab (Yervoy) to standard chemotherapy could improve outcomes for people with early-stage non-small cell lung cancer that can be surgically removed. The study enrolled 505 participants a…

This early-phase study tested a new drug called BAT8006 in 216 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the best dose for future studies. This is not a cure, but a step toward better control…

This study tested whether giving personalized radiation doses based on PET scans during treatment could improve local control in patients with inoperable stage III non-small cell lung cancer. 158 participants received either standard radiation or a higher, tailored dose to areas …

This phase 2 trial tested a combination of the immunotherapy drug durvalumab with two chemotherapy drugs (doxorubicin and ifosfamide) in 16 people with a rare and aggressive type of lung cancer called pulmonary sarcomatoid carcinoma. The goal was to see if the combination could s…

This early-stage trial tested an oral drug called JAB-3312 in 40 adults with advanced solid tumors (like lung, colon, or breast cancer) that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects. Researchers also looked …

This study tested whether combining the immunotherapy atezolizumab (Tecentriq) with the targeted drug cabozantinib works better than the standard chemotherapy docetaxel for people with advanced non-small cell lung cancer that has worsened after prior treatment. The trial enrolled…

This early-phase study tested the safety of combining two targeted drugs, dacomitinib and osimertinib, in 22 people with a specific type of advanced lung cancer (EGFR mutant). Participants had not received similar targeted therapy before. The goal was to find the safest dose and …

This phase 2 trial tested two drugs, amivantamab and lazertinib, in 43 adults with a specific type of lung cancer (EGFR-mutant) that had spread to the brain and worsened after previous treatments. The goal was to see if the combination could shrink or control brain tumors. Both d…

This early-phase trial tested an experimental drug called ezabenlimab, alone or combined with another drug (BI 754111), in 146 Asian patients with advanced solid tumors. The main goals were to check safety, find the right dose, and see if the combination shrinks tumors in cancers…

This Phase 3 trial tested a targeted cancer pill called pyrotinib against standard chemotherapy (docetaxel) in 151 people with advanced non-squamous non-small cell lung cancer that has a specific HER2 mutation. All participants had already tried platinum-based chemo without succe…

This phase 2 trial tested the drug furmonertinib in 24 people with advanced non-small cell lung cancer (NSCLC) that has EGFR mutations and spread to the brain. The goal was to see how long the drug could keep brain tumors from growing. Participants took a daily pill, and research…

This study tested a new way to do lung cancer surgery without using a breathing tube or ventilator. Instead, patients breathe on their own during the operation. The goal was to see if this 'tubeless' method causes less lung injury, helps patients recover faster, and reduces pollu…

This early-stage trial tested the safety of a new drug called SGN-B6A in 6 Chinese patients with advanced solid tumors (lung, head and neck, esophageal, stomach cancers). The main goal was to identify side effects and see how the body processes the drug. It is a first step to see…

This early-phase trial tested an experimental drug called BMS-986315, alone or combined with other immunotherapies (nivolumab or cetuximab), in 44 people with advanced solid tumors like head and neck, lung, or kidney cancer. The main goals were to check safety and find the right …

This phase 3 trial tested whether adding two immunotherapy drugs (nivolumab and ipilimumab) to standard chemotherapy helps people with stage IV non-small cell lung cancer live longer. About 719 patients who had not received prior treatment took part. The study compared the combin…

This study tested a new drug (TJ004309) combined with an approved immunotherapy (atezolizumab) in 25 people with advanced ovarian, head and neck, lung, gastrointestinal, or triple-negative breast cancers. The goal was to see if the combination could shrink tumors. Participants ha…

This study tested adding a precise type of radiation (SBRT) to standard targeted therapy pills for people with stage IV lung cancer that has specific gene changes (EGFR, ALK, or ROS1). The goal was to see if this combination could delay the cancer from spreading to new areas. 27 …

This early-phase trial tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy and radiation is safe for people with stage II to IIIB non-small cell lung cancer. Twenty-three participants received the combination to find the best dose and check for sid…

This early-stage trial tested a new treatment for people with advanced non-small cell lung cancer that had grown after standard therapy. Researchers took patients' own immune cells, genetically modified them to recognize and attack cancer cells, and infused them back after chemot…

This early-stage study tested whether adding PB101 (a patient's own natural killer cells) to standard targeted therapy is safe for people with advanced EGFR-mutated non-small cell lung cancer. Eight adults with stage IIIB/IV disease received the combination. The main goal was to …

This early-phase study tested a new drug called ABBV-155, given alone or with standard chemotherapy (paclitaxel or docetaxel), in 168 adults with advanced solid tumors that had come back or stopped responding to treatment. The main goal was to find a safe dose and check for early…

This study tested a new drug, TAK-981, combined with the immunotherapy pembrolizumab in 161 adults with advanced or metastatic solid tumors that could not be cured. The main goals were to check safety and see if the combination could shrink tumors. Participants received treatment…

This early-phase trial tested a personalized immunotherapy for people with advanced solid tumors. Doctors removed a sample of each patient's tumor, grew the immune cells (TILs) in a lab, and then infused them back along with another drug. The goal was to see if this approach is s…

This early-stage study tested a new drug called BAT1308 in 59 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and check for side effects. Researchers also looked at how the drug moves through the body. Th…

This study tested whether a subcutaneous (under-the-skin) injection of the immunotherapy drug atezolizumab works as well as the standard intravenous (IV) infusion in people with advanced non-small cell lung cancer who had already tried platinum-based chemotherapy. The trial enrol…

This early-phase study tested adding the drug pirfenidone to standard chemotherapy for people with advanced non-small cell lung cancer. The main goals were to find a safe dose and see if the combination could shrink tumors. 48 participants were enrolled, and the study is now comp…

This study looked at whether giving palliative radiation to several tumor sites before starting standard immunotherapy and chemotherapy can help people with metastatic non-small cell lung cancer. Fifty adults with cancer that had spread and low PD-L1 levels received radiation to …

This study tested a new experimental drug called JS004, combined with another immunotherapy (toripalimab) and standard chemotherapy, in 119 people with advanced lung cancer. The goal was to see if the combination is safe and might help shrink tumors. The trial has finished, but r…

This study tested whether using a non-invasive ventilation machine for at least 7 days before lung cancer surgery could reduce lung and heart complications. The trial included 300 patients with lung cancer who also had breathing problems, obesity, or heart failure. The goal was t…

This study tested a combination of two drugs, atezolizumab and bevacizumab, as the first treatment for people with advanced non-squamous lung cancer that has a high number of genetic mutations. The goal was to see if this drug pair could slow down cancer growth. The trial enrolle…

This study tested a combination of the immunotherapy drug pembrolizumab with two investigational drugs (MK-4830 or MK-0482) in 102 people with advanced non-small cell lung cancer that had not been treated before and tested positive for a protein called PD-L1. The main goal was to…

This early-phase trial tested a new way to treat advanced cancers that have spread. It combined a special type of radiation with two immunotherapy drugs (MEDI4736 and tremelimumab) to see if the combination is safe and tolerable. The study included 53 adults with advanced melanom…

This trial tested different doses of proton beam therapy combined with standard chemotherapy for people with stage 2-3 non-small cell lung cancer that cannot be surgically removed. The goal was to find the best radiation dose to control the cancer. Twenty participants received tr…

This early-stage trial tested a new drug called CFT1946, alone or with other drugs, in 89 adults with solid tumors that have a BRAF V600 mutation, including melanoma, lung, colon, and thyroid cancers. The main goals were to check safety and find the best dose. The study is comple…

This study tested a drug called trastuzumab deruxtecan in 152 people with advanced non-small cell lung cancer that has a specific genetic change (HER2 mutation) and has stopped responding to standard chemotherapy. The drug is given by IV every three weeks and aims to shrink tumor…

This early-phase trial tested whether adding copanlisib to the standard immune therapy durvalumab is safe for people with stage III non-small cell lung cancer that cannot be removed by surgery. The study enrolled 11 participants who had already received chemotherapy and radiation…

This phase 3 trial tested whether patients with advanced non-small cell lung cancer (NSCLC) who received initial immunotherapy (nivolumab and ipilimumab) for 6 months could safely stop treatment and be monitored, instead of continuing therapy indefinitely. The study enrolled 265 …

This Phase 2 trial tested whether adding OSI-906 to erlotinib (Tarceva) as maintenance therapy could help people with advanced non-small cell lung cancer (NSCLC) who had not progressed after initial chemotherapy. The study enrolled 205 participants and compared the combination ag…

This Phase 2 trial tested whether adding the experimental drug OSI-906 to the standard targeted therapy erlotinib (Tarceva) could help people with advanced non-small cell lung cancer that has a specific EGFR gene mutation. The study enrolled 88 people who had not received prior c…

This early-phase trial tested a combination of three drugs—afuresertib, sintilimab, and chemotherapy—in 22 adults with solid tumors (including lung, cervical, and stomach cancers) that had stopped responding to prior immunotherapy. The goal was to find a safe dose and see if the …

This study tested an oral drug called GFH925 in 334 people with advanced solid tumors that have a specific KRAS G12C mutation. The trial aimed to find the safest dose and check if the drug can shrink tumors in cancers like lung and colorectal cancer. Results will help decide if l…

This early-phase trial tested a combination of two drugs—nivolumab, a standard immunotherapy, and plinabulin, an experimental drug that attacks tumor blood vessels—in 18 people with advanced non-small cell lung cancer that had worsened after chemotherapy. The main goals were to f…

This study tested giving the cancer drug nivolumab as a shot under the skin (instead of through an IV) to people with advanced cancers like lung, kidney, melanoma, liver, and colorectal cancer. The main goal was to see how the drug moves in the body and to check for side effects.…

This study tested an experimental drug called BDB001 in people with advanced solid tumors (like skin, lung, or kidney cancer) that had stopped responding to standard immunotherapy. The goal was to see if BDB001 could shrink tumors or slow their growth. Only one person took part, …

This study tested a new treatment approach for people with inoperable non-small cell lung cancer. It combined MRI-guided radiation therapy with chemotherapy and an immunotherapy drug called durvalumab. The goal was to see if this combination is safe and effective at controlling t…

This early-phase study tested an experimental drug called GDC-1971 combined with either osimertinib (for lung cancer) or cetuximab (for colorectal cancer) in 10 people with advanced cancers that had spread. The main goal was to check safety and find the right dose. Researchers al…

This study tested a combination of two experimental drugs (BI 836880 and ezabenlimab) in 252 adults with advanced non-squamous lung cancer and other solid tumors. The first part found the safest dose; the second part checked if the combo could shrink tumors. Participants received…

This study tested a combination of a cancer vaccine (TG4010) and an immunotherapy drug (nivolumab) in 13 people with advanced non-small cell lung cancer who had already received other treatments. The goal was to see if the combination could shrink tumors or stop them from growing…

This study tested whether adding high-dose, precisely targeted radiation to standard immunotherapy can improve outcomes for people with stage IV non-small cell lung cancer. Forty-five adults who were already on immunotherapy received radiation to some of their tumors. Researchers…

This early-phase study tested a new drug called boserolimab (MK-5890), either alone or combined with the immunotherapy pembrolizumab (KEYTRUDA), in 182 adults with advanced solid tumors, including lung and breast cancers. The main goals were to check safety and how the drug moves…

This study tested whether the immunotherapy drug pembrolizumab (Keytruda) can help people with oligometastatic non-small cell lung cancer (NSCLC) who have already completed curative treatment. Fifty-one participants received pembrolizumab every three weeks for up to 16 cycles. Th…

This Phase 2 study tested the drug lorlatinib in 109 people in China with advanced ALK-positive non-small cell lung cancer whose disease had progressed after treatment with other ALK inhibitors. The goal was to see how many patients' tumors shrank or disappeared. The trial is now…

This study tested whether combining the immunotherapy drug nivolumab with another drug (ipilimumab) or with standard chemotherapy could help people with advanced non-small cell lung cancer live longer or keep their cancer from growing. About 2,700 patients who had not received pr…

This study tested whether adding an immunotherapy drug (MEDI4736) to standard chemotherapy before surgery helps people with stage IIIA non-small cell lung cancer. 68 participants received the combination treatment. The goal was to see if this approach improves how long people liv…

This early-stage trial tested a combination of an immunotherapy drug (atezolizumab) and precise radiation therapy (SBRT) in 20 people with stage I non-small cell lung cancer who couldn't have surgery. The main goal was to find the safest dose and check for side effects. Researche…

This study tested a new drug called DF9001, which helps the body's natural killer cells attack cancer cells. It was given alone or with another immunotherapy (pembrolizumab) to 24 adults with advanced solid tumors that have the EGFR protein. The goal was to check safety and find …

This study looked at how well the drug Tagrisso (osimertinib) works and how safe it is for people with a certain type of lung cancer (non-small cell lung cancer with EGFR mutations) in everyday medical practice. Over 900 patients in Korea were observed while taking Tagrisso as th…

This early-stage study tested a new drug called PRT3789, alone or with chemotherapy (docetaxel), in people with advanced solid tumors that have a specific change in the SMARCA4 gene. The main goals were to check safety, find the best dose, and see if the drug shrinks tumors. 135 …

This phase II trial tested a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus chemotherapy (paclitaxel) in 46 people with untreated metastatic non-small cell lung cancer. The goal was to see if the mix could slow cancer growth and be safe. Results may point …

This early-phase study tested an experimental drug called MK-4830, either by itself or combined with other cancer therapies like pembrolizumab, in 470 people with advanced solid tumors. The main goals were to check safety, find the right dose, and see if tumors shrank. The study …

This early-phase study tested a combination of two immunotherapy drugs, BGB-A445 and tislelizumab, in 204 people with advanced solid tumors including lung, head and neck, and nasopharyngeal cancers. The main goals were to check safety and find the best dose. The trial is now comp…

This study tested the immunotherapy drug durvalumab in 50 patients with advanced lung cancer who were too weak for standard chemotherapy. The goal was to see if the drug is safe and helps control the disease. Researchers focused on side effects and how well patients responded.

This phase 2 trial tested the drug serplulimab (an immunotherapy) combined with standard chemotherapy in 30 people with stage II-IIIA non-small cell lung cancer that could be surgically removed. The treatment was given before and after surgery to see if it could shrink tumors and…

This phase 2 trial tested whether adding two newer drugs—GFH018 and toripalimab—to standard chemoradiotherapy could help people with stage III non-small cell lung cancer that cannot be surgically removed. The study enrolled 65 adults and measured how many patients saw their tumor…

This early-phase study tested an experimental drug called ABBV-CLS-579, given alone or with other cancer treatments, in 101 adults with advanced solid tumors that had stopped responding to standard therapy. The main goal was to find safe and tolerable doses, not to prove the drug…

This study tested a new two-drug combination (bemcentinib plus pembrolizumab) in 99 adults with advanced lung cancer that had already been treated. The goal was to see if the combination could shrink tumors or stop them from growing. Participants received both drugs by mouth or I…

This phase 2 trial tested a new drug called BA3011, alone or with an immunotherapy, in 85 adults with advanced non-small cell lung cancer that had worsened after standard treatments. The goal was to see if the drug could shrink tumors and how safe it was. The study is now complet…

This study tested whether adding an experimental immunotherapy drug (ociperlimab) to a standard immunotherapy (tislelizumab) plus chemotherapy could help people with advanced non-small cell lung cancer. The trial involved 272 patients whose cancer had spread or could not be remov…

This study tested a new drug called AZD3759 against standard targeted therapies (erlotinib or gefitinib) in 492 people with advanced EGFR-mutant lung cancer that had spread to the brain. The goal was to see if AZD3759, which is designed to better reach the brain, could keep the c…

This phase 3 trial tested two targeted drugs, brigatinib and alectinib, in 248 people with advanced ALK-positive non-small-cell lung cancer whose cancer had worsened after taking crizotinib. Participants were randomly assigned to take either brigatinib or alectinib daily. The mai…

This early-phase study tested an experimental drug called TPST-1495, taken as a pill, either alone or combined with the immunotherapy Keytruda (pembrolizumab). The trial included 89 people with advanced solid tumors like colorectal, lung, head and neck, and endometrial cancers wh…

This large Phase 3 trial tested whether adding aflibercept (a drug that blocks blood vessel growth) to standard chemotherapy (docetaxel) could help people with advanced non-small cell lung cancer live longer. Over 900 participants who had already tried one platinum-based treatmen…

This Phase 3 trial tested whether adding the targeted drug lenvatinib to standard chemotherapy plus the immunotherapy pembrolizumab helps people with advanced nonsquamous non-small cell lung cancer live longer without their cancer growing. The study enrolled 201 adults in China w…

This study tested two drugs—auranofin (originally for arthritis) and sirolimus (an immune suppressant)—in 29 people with advanced or recurrent lung cancer who had no standard options left. The goal was to find the safest dose and see if the combination could slow cancer growth. T…

This early-phase trial tested an experimental immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers who had signs of remaining disease after standard treatment. The therapy aims to train the immune system to attack…

This study looked at whether a special PET scan (18FDG dual-point) can tell the difference between real tumor growth and harmless inflammation caused by immunotherapy. Researchers studied 100 people with advanced lung cancer or melanoma who were being treated with drugs like nivo…

This early-phase trial tests whether a PET/CT scan using an investigational tracer called zirconium Zr 89 crefmirlimab berdoxam can safely and effectively spot CD8+ T cells—key immune cells that attack cancer—in people with metastatic non-small cell lung cancer. Participants are …

This study investigates whether a liquid biopsy taken from the airways during a bronchoscopy can help diagnose lung cancer and identify genetic mutations. The approach aims to be less invasive and faster than traditional tissue biopsies. Researchers will compare the accuracy of t…

This study tests a new, ultra-sensitive blood test (NGS) to detect EGFR gene mutations in patients with advanced lung cancer. Researchers will compare it to the current standard test using stored blood samples from 130 patients. The goal is to see if the new method finds more mut…

This study aimed to create easy, non-invasive tests using blood and saliva to find markers of certain cancers, like breast and lung cancer. Researchers worked with 250 adults who had these cancers but hadn't started treatment yet. The goal was to improve early detection and monit…

This study tested whether a simple breath test can predict if cancer patients will respond to immunotherapy drugs. Researchers used an electronic nose device to analyze breath samples from 190 patients with lung, melanoma, kidney, bladder, or head and neck cancers. The goal is to…

This study tested whether a blood test can detect ALK gene rearrangements in lung cancer patients, which currently requires an invasive tumor biopsy. Researchers analyzed circulating tumor cells from blood samples of 206 patients with advanced lung cancer. The goal was to see if …

This study looked at whether a blood test can find gene changes in people with advanced lung cancer. 22 adults gave a blood sample, and the results were compared to standard tissue tests. The goal was to see if the blood test is a reliable and practical option for guiding treatme…

This study looked at whether a simple blood test (liquid biopsy) can detect EGFR gene mutations in people with advanced non-small cell lung cancer. Researchers collected blood samples from 581 patients and compared the results with standard tissue testing. The goal was to see if …

This study tested whether a new type of PET scan, which looks for a protein called PD-L1 on cancer cells, can predict how well patients with advanced lung cancer will respond to the immunotherapy drug nivolumab. Eighty patients received the scan before starting treatment. Researc…

This study tested whether changing how FDG PET/CT scans are taken and processed can make them more accurate for staging lung cancer. Thirty adults with non-small cell lung cancer were enrolled. The goal was to see if better imaging could help doctors determine if cancer has sprea…

This study tested a special breathing technique during PET scans to get clearer images of lung tumors. 103 people with small lung nodules (under 35 mm) had both a standard PET scan and an extra scan where they held their breath. The goal was to see if this reduces blurring from b…

This phase III trial tests whether the immunotherapy drug durvalumab (MEDI4736) can prevent non-small cell lung cancer from returning after patients have surgery and possibly chemotherapy. Participants have completely resected stage IB, II, or IIIA lung cancer and are randomly as…

This phase II trial tested whether the immunotherapy drug pembrolizumab (Keytruda) can prevent lung cancer in 45 people with high-risk lung nodules or early-stage non-small cell lung cancer. Participants received pembrolizumab intravenously, and researchers tracked tumor response…

This early-phase study tested a vaccine called CIMAvax-EGF in 20 people at high risk for lung cancer or survivors at risk of recurrence. The vaccine works by helping the body make antibodies against a protein that can fuel cancer growth. Researchers checked for side effects and m…

Researchers compare two chest drain sizes, 20-Fr and 24-Fr, in people having part of a lung removed for early-stage lung cancer. After surgery, each participant receives one of the two drains to clear fluid and air from the chest. The trial tracks complications such as collapsed …

Researchers test a guided exercise program for people aged 60 and older recovering from lung cancer surgery. The program combines breathing exercises, shoulder training, and strength work, taught through videos and a manual. The trial measures how far participants can walk in six…

This trial tests whether a structured patient education program can lower the risk of severe immune-related side effects in people receiving immunotherapy for certain cancers, including melanoma, lung, kidney, and head and neck cancers. Participants either attend five educational…

This pilot study tests whether a daily herbal supplement made from Lindera obtusiloba can improve quality of life for people with non-small cell lung cancer who are receiving PD-1 or PD-L1 inhibitor immunotherapy. About 20 adults will take the supplement for 8 weeks alongside the…

This study tests whether teaching family caregivers about lung cancer care—through a handbook and personalized guidance—can reduce stress and improve quality of life for patients undergoing lung cancer surgery. The trial involves 160 patients and their caregivers, with some recei…

This study looks at two ways of delivering palliative care—specialized support to ease symptoms and stress—for people recently diagnosed with advanced lung cancer. One approach starts with basic palliative care and adds more if needed, while the other provides full palliative car…

This trial tests whether a wearable sensor called the Alio Smart Patch can help catch early signs of febrile neutropenia, a serious infection risk from chemotherapy. Thirty adults with certain cancers will wear the patch and a glucose monitor at home, with a remote care team watc…

This study tested whether a 4-week home exercise program, guided by a wearable fitness device and supervised remotely, could help lung cancer patients get in better shape before surgery. Thirty people with early-stage non-small cell lung cancer participated. The goal was to see i…

This study tested whether a personalized exercise program helps people with early-stage lung cancer or cancer that spread to the lungs recover better after surgery. 182 participants were randomly assigned to either the exercise program or usual care. The main goal was to see if t…

This study tested whether personalized motivational messages sent via apps like WhatsApp could improve thinking skills and physical activity in lung cancer survivors who have memory or concentration problems. 124 survivors wore activity trackers and received custom messages for t…

This study tested an investigational drug called ponsegromab in 187 adults with lung, pancreatic, or colorectal cancer who also had cachexia—a condition causing severe weight loss, loss of appetite, and fatigue. The goal was to see if ponsegromab could help patients gain weight a…

This early-phase trial tested a treatment called photodynamic therapy for people with advanced lung cancer that blocks airways. Patients received a light-sensitive drug followed by a laser to activate it inside the tumor. The goal was to see if the treatment is safe and can shrin…

This study tested two different radiotherapy schedules for people with advanced non-small cell lung cancer. One group received the standard 6-week course, while the other had a shorter 4-week course guided by PET scans. The main goal was to see how patients felt during and after …

This study tested whether an education and support program can help family caregivers of cancer patients feel more confident and less anxious. About 484 caregivers and patients took part. Researchers compared different types of support to see which worked best.

This study tested whether a family-supported palliative care program could improve quality of life and emotional well-being in 110 people with advanced lung cancer. Participants were randomly assigned to either the family-supported program or standard nursing care for 8 weeks. Th…

This study tested a low-cost, portable exercise program for people with non-small cell lung cancer after surgery. The goal was to help them manage severe fatigue and improve their quality of life. 235 adults took part, and the program was designed to be safe and practical for nea…

This study tested the safety of a special radiation schedule called Quad Shot for people with stage IV non-small cell lung cancer who are also receiving chemotherapy or immunotherapy. The Quad Shot delivers radiation in just 2 days per cycle, up to 3 cycles, to make it easier to …

This study tested a program that teaches couples communication skills when one partner has advanced cancer. About 440 patients and their partners took part, with half receiving the training and half getting general healthy living information. The goal was to see if the training c…

This study looked at whether people with non-small cell lung cancer prefer getting the drug atezolizumab as a shot under the skin (subcutaneous) or through an IV drip. About 179 patients tried both methods and reported which they liked better. The goal was to see if the shot is m…

This study tested a supportive care program for adults aged 60 and older with advanced lung cancer. The program combined physical therapy and relaxation exercises to help improve physical function and emotional wellbeing. Researchers measured how well participants stuck with the …

This study tested whether a nutritional supplement with essential amino acids could help lung cancer patients who are losing weight build more protein in their bodies. 41 patients with advanced non-small cell lung cancer took part. The goal was to see if this supplement could red…

This study tested a new bendable surgical tool (SurgeoFlex Grasp) against a standard rigid tool in 100 adults with early-stage lung cancer undergoing keyhole surgery. The goal was to see if the flexible tool makes lymph node removal faster, reduces instrument clashes, and eases s…

This study looks at how doctors currently diagnose lung and breast cancer using tissue samples. It will also test whether artificial intelligence (AI) can help analyze these samples faster and more accurately. Researchers will review records from 600 patients to measure diagnosis…

This study looks at why lung cancer cells stop responding to a class of drugs called EGFR inhibitors. Researchers will collect blood samples from 80 patients over time to track changes in tumor DNA and cells. The goal is to understand the early steps of drug resistance and find w…

This trial tests whether a 15-minute educational video and a list of suggested questions can improve understanding of immunotherapy among patients with advanced cancer and their caregivers. Participants are randomly assigned to receive the educational materials or usual care, and…

This trial is testing whether using whole-body PET/CT scans and liquid biopsies (blood tests that detect cancer DNA) can improve the follow-up care of people who have completed treatment for early-stage non-small cell lung cancer. The goal is to see if these advanced tools can fi…

This study follows over 2,700 people with bladder, lung, or liver cancer who are receiving the drug atezolizumab as part of their normal treatment. Researchers are tracking how long patients live and how well the drug controls their cancer outside of a controlled clinical trial. …

This study follows 1,200 people in China newly diagnosed with advanced non-small-cell lung cancer (stage IIIB/IV) that cannot be removed by surgery. Researchers will collect information from medical records and follow patients over time to see what treatments they receive, how lo…

This 100% remote study surveys 250 people diagnosed with non-small cell lung cancer before age 50. Participants answer questions about their environment, lifestyle, and family history, and may donate blood. The goal is to uncover factors linked to genetic changes that drive young…

This study interviews 55 patients with resectable non-small cell lung cancer and their doctors in the US, Germany, and Japan. The goal is to understand what treatment features they value most, such as effectiveness or side effects. Results may help align care with patient priorit…

This study tests a new AI tool called GAPS-Agent that helps doctors plan surgeries for lung cancer. The tool is designed to assist less experienced doctors in making complex decisions. Researchers will compare AI-generated plans to those from a standard AI, and expert surgeons wi…

This study looks at 248 lung cancer patients having surgery to see if the length of time they quit smoking before the operation affects their risk of complications like pneumonia or heart issues. Researchers compare recent quitters and long-term nonsmokers to find the best timing…

This study looks at how anti-tumor T-cell responses change in people with lung or head-and-neck cancer who are receiving radiochemotherapy. Researchers will collect blood and tumor samples to track immune markers. The goal is to understand whether this standard treatment can boos…

This study looked at 115 adults with advanced non-small cell lung cancer to see if muscle loss (sarcopenia) and a blood-based score called CTI affect how well immunotherapy works. Researchers reviewed medical records to measure muscle on CT scans and calculate CTI from routine bl…

This study is for people with early-stage lung cancer whose cancer returned after taking the drug osimertinib. Researchers will analyze tumor or blood samples to find gene changes linked to the recurrence. The goal is to better understand why some cancers come back, which could h…

This study explores whether artificial intelligence can predict the stage and survival of non-small cell lung cancer by analyzing CT and PET scans. Researchers will train a deep learning model using existing medical records from 156 patients who had lung cancer surgery. The goal …

This study investigates whether a simple blood test (liquid biopsy) can track how advanced non-small cell lung cancer changes during immunotherapy or targeted therapy. Researchers will analyze tumor DNA circulating in the blood to see if it can predict treatment response and dete…

This study looked at 30 people with early-stage non-small cell lung cancer who had surgery. Researchers collected blood from a vein near the tumor and from a regular arm vein to study tiny particles called exosomes. The goal was to see if these particles could help predict whethe…

This completed study looked at 40,000 people with metastatic cancer who received the drug nivolumab. Researchers compared the old way of dosing (based on body weight) with a newer, simpler fixed dose. They used national health data to see if the fixed dose was just as good and mo…

This completed study in Greece enrolled 200 people with stage 4 non-small cell lung cancer. Researchers used genetic testing to map each tumor's unique features and gave half the patients access to a digital platform to report side effects. The goal was to see if combining person…

This early-phase trial tested a precise, high-dose radiation technique called stereotactic body radiotherapy (SBRT) in 42 patients with breast, lung, or prostate cancer that had spread to several places in the body. The main goal was to find the safest dose and check for side eff…

This completed study looked at 44 patients who had lung cancer surgery to understand how the arteries in the lungs can vary from person to person. Using CT scans and 3D models, researchers mapped these variations to help surgeons avoid complications during lobectomy. The goal was…

This study looked at whether a blood test measuring DNA fragments can detect leftover cancer after lung cancer surgery. Researchers followed 133 patients with early-stage lung cancer for one year after their operation. The goal was to see if changes in the DNA test could predict …

This study uses lung ultrasound to measure how the lungs change after surgery to remove part of a lung due to cancer. Researchers will check lung aeration before surgery, right after, and 24 hours later in about 32 adults. They aim to see if ultrasound findings relate to oxygen l…

This completed study enrolled 336 people with non-small cell lung cancer to collect detailed family cancer histories using a questionnaire. Researchers want to see if certain patterns of cancer in relatives, along with smoking and other risk factors, can help identify patients wh…

This study looked at whether a blood test called ISET can find circulating tumor cells in people with early-stage non-small cell lung cancer. Researchers checked blood samples from 256 patients before surgery to see if these cells were linked to cancer stage, type, and survival. …

This study looked at whether measuring procalcitonin (PCT) levels in the blood could help detect infections earlier in people with stage IV non-small cell lung cancer starting chemotherapy. Researchers enrolled 45 patients and took a PCT blood sample before their first chemo sess…

This study explored sleep disorders in 37 adults with non-small cell lung cancer. Participants filled out questionnaires about their sleep, symptoms, mood, and quality of life. The goal was to create a guide to help doctors diagnose and treat sleep issues in this group, ultimatel…

This study tested whether a special 4D PET-CT scan can help doctors better target radiation for lung cancer. Seven patients with non-small cell lung cancer received both a standard CT scan and a 4D PET-CT scan before radiotherapy. Researchers compared the tumor volumes identified…

This study looked at 302 patients with advanced non-small cell lung cancer in Greece who were treated with a combination of nivolumab, ipilimumab, and chemotherapy as their first therapy. Researchers tracked patient characteristics, treatment patterns, and survival rates over tim…

This study looked at 24 people with lung or esophageal cancer who received radiation or chemo-radiation near the heart. Participants wore a small heart monitor to catch any heart changes that might otherwise go unnoticed. The goal was to see how often heart problems occur after s…

This completed study looked at 150 people with advanced non-small cell lung cancer to see if proteins and metabolites in blood and urine could help monitor how well immunotherapy is working. Researchers used mass spectrometry to measure these markers before, during, and after tre…

This study analyzed blood samples from 50 adults with advanced ALK-positive lung cancer whose disease had stopped responding to one or two ALK inhibitors. The goal was to identify genetic changes in the cancer that cause drug resistance. By matching these changes to the right nex…

This study tested whether implanting tiny gold markers near spinal tumors helps deliver radiation more accurately. Researchers also checked if giving slightly more radiation to the nearby esophagus is safe, which might improve tumor control. The study involved 41 adults with vari…

This study compared two ways for surgeons to see the borders between lung segments during surgery for early-stage non-small cell lung cancer. One method uses a green dye and a special camera, the other uses a modified inflation-deflation technique. The trial involved 272 patients…

This phase 2 trial studied 50 people with non-small cell lung cancer to see if differences within a tumor (called heterogeneity) affect how well treatments work. Patients received one of four drugs based on their tumor's genetic changes: atezolizumab (immunotherapy), vemurafenib,…

This study looked at the nutrition and body composition of 25 adults with non-small-cell lung cancer who were taking the drug osimertinib. Researchers measured weight, muscle mass, and strength to see how common malnutrition and muscle loss were, and how these affected quality of…

This study looked at 4000 people with advanced lung cancer who had a specific gene mutation (EGFR) and were taking a targeted pill. The goal was to find the best time to add focused radiation to shrink any remaining tumors. Researchers tracked when tumors shrank the most and wher…

This study looked at chemical fingerprints (metabolites) in blood, lung tissue, and exhaled breath from 74 people with either non-small cell lung cancer or harmless lung nodules. The goal was to find differences that could help diagnose lung cancer without invasive procedures. Re…

This study looked back at medical records of 240 adults in Poland who received a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus chemotherapy as their first treatment for advanced non-small cell lung cancer. The goal was to see how well the treatment worked…

This completed study tested whether a new biomarker called 'mass response' can predict how well a cancer therapy will work. Researchers collected tumor cells from 72 patients with various cancers through fluid drainage or biopsies. The goal was to see if this biomarker could guid…

This study looked at 182 older adults with blood cancer or lung cancer to see if a special calculator could predict who would have severe side effects from chemotherapy. Researchers measured patients' fitness before and after treatment to better understand how well they could han…

This study looks at whether the drug T-DXd works better than standard treatments for people with several types of HER2-positive solid tumors. Researchers will compare data from previous T-DXd trials with real-world medical records of patients who received standard care. The goal …

This study looked back at medical records of 60 people with advanced non-small cell lung cancer who received standard immunotherapy (anti-PD-1/PD-L1 drugs). Researchers checked whether those who also took beta-blockers (commonly used for heart conditions) had different outcomes, …

This study looked at whether people with advanced cancers (melanoma, kidney, or lung cancer) receiving their first immunotherapy treatment could successfully collect small blood samples at home using a finger-prick method. The goal was to see if this approach is practical and rel…

This study looked at whether a simple blood test (liquid biopsy) can detect a specific resistance mutation called T790M in patients with advanced non-small cell lung cancer whose tumors stopped responding to initial targeted therapy. Researchers followed 70 patients in Tunisia, c…

This study examined pieces of the Met receptor protein in tumor and healthy tissue from 56 people with non-small cell lung cancer. Researchers used blood and tissue samples taken during surgery or biopsy to see which Met fragments are present and whether they are active. The goal…

This study created a detailed database of 518 adults with non-small cell lung cancer in the Nord Pas de Calais region of France. Researchers collected clinical information and genetic mutation data to see how factors like age, smoking, and cancer stage relate to specific mutation…

This study looked back at the medical records of 833 people with advanced non-small cell lung cancer to understand how they were treated and how long they lived. Researchers collected information from doctors' surveys across multiple countries. The goal was to learn about real-wo…

This study looked at how doctors currently treat patients with a type of advanced lung cancer that is not causing symptoms and cannot be cured. It followed 46 patients who either received radiation therapy right away or waited until symptoms appeared. The goal was to understand t…

This completed phase 1 study in 28 healthy adults examines how the experimental cancer drug calderasib (MK-1084) changes the way the body processes two common drugs: midazolam and digoxin. Researchers measure drug levels in the blood after giving these drugs with and without cald…

This study looked at the safety and effectiveness of the drug Vizimpro in 188 adults with advanced lung cancer who had specific gene mutations. It was an observational study, meaning patients received their normal treatment and researchers simply collected data on side effects an…

This study aimed to find immune-related biomarkers that could predict how well patients with non-small cell lung cancer respond to the drug atezolizumab. Researchers analyzed blood and tumor samples from 100 participants to track immune cell changes and genetic markers. The goal …

This study tested a screening platform to check tumor tissue for specific biomarkers. The goal was to see if patients with solid tumors could be eligible for a linked Roche clinical trial. About 470 participants provided tumor samples for testing. The study is now complete and fo…

This completed study looked at nearly 5,000 people with non-small cell lung cancer to see if information from electronic health records could produce the same results as a famous clinical trial called FLAURA. Researchers compared patients who started taking osimertinib to those o…

This study looked at whether the time of day affects the number of cancer cells in the blood of people with advanced lung cancer. Researchers took blood samples from 27 patients at 4 a.m. and 10 a.m. before starting treatment. The goal was to see if circadian rhythms influence ho…

This study tracked 51 lung cancer patients before and after video-assisted thoracoscopic surgery to see how much time they spent lying down, sitting, or standing. Researchers also looked at what prevented patients from moving more. The goal was to understand barriers to early mob…

This study followed 196 people with advanced lung or stomach cancer who had not yet received treatment. Researchers wanted to see if emotional distress before starting immunotherapy, along with certain blood markers of inflammation and metabolism, could predict how long patients …

This completed study from Argentina looked at 70 patients with resectable non-small cell lung cancer who received nivolumab (Opdivo) plus chemotherapy before surgery. Researchers wanted to see how well this combination works in real-world practice, measuring how many patients had…

This study looked at 98 adults with cancers like melanoma and lung cancer who were starting immunotherapy. Researchers measured inflammatory markers in their blood to understand how the body reacts to these drugs. The goal was to find ways to better manage side effects from treat…

This study tested a new cone-beam CT scanner designed to take clearer images while patients are on the radiotherapy couch. 41 adults with head-and-neck, lung, breast, abdominal, or pelvic cancer each had one or two scans with the new device. The goal was to see if the images were…

This study looked at 40 people with advanced non-small cell lung cancer who were starting treatment with the drug pembrolizumab. Researchers used special PET scans after each of the first three doses to see how the cancer's metabolism changed. The goal was to find out if early sc…

This study looked at whether a special type of PET scan called parametric imaging can better predict if lung cancer will come back within a year after chemoradiation. Researchers compared it to standard PET scans in 40 patients with non-small cell lung cancer. The goal is to see …

This study tested a new blood test (liquid biopsy) to find cancer markers in 135 people with head and neck, lung, or skin cancer. The goal was to see if the blood test works as well as a standard tissue biopsy. The study did not provide treatment but aimed to improve how doctors …

This study looked at whether a simple blood test can monitor lung cancer progression without needing to sample the tumor directly. Researchers checked for genetic changes in the blood of 200 lung cancer patients. The goal was to see if this non-invasive method could track how the…

This study tested whether a combination of 6 markers from tumor tissue could predict how well patients with advanced non-small cell lung cancer respond to first-line treatment with pembrolizumab (immunotherapy) plus chemotherapy. Researchers analyzed tissue samples from 106 patie…

This study looked at people with advanced solid tumors (like lung, bladder, or melanoma) who had been on immunotherapy for one year and whose disease was stable. Half stopped treatment and half continued. The goal was to see if stopping early affected how long until the cancer pr…

This study followed 100 people with advanced EGFR-mutant lung cancer who were taking drugs called EGFR-TKIs (erlotinib, dacomitinib, afatinib, or osimertinib). The goal was to see how often these drugs cause heart problems, specifically a drop in the heart's pumping ability. Rese…

This completed study observed 178 patients with advanced cancer, chronic kidney failure, or chronic lung diseases to assess their palliative care needs and survival factors. Researchers used two scoring tools to evaluate when and how to best introduce palliative care alongside re…

This study looked at 100 people with advanced non-small cell lung cancer to see if changes in tumor DNA in the blood (ctDNA) can predict how well treatment is working. Researchers took blood samples before treatment, at 3 weeks, and at 9 weeks. The goal was to see if a rise or fa…

This study involved over 2,000 people with early-stage non-squamous lung cancer who had surgery. Researchers wanted to see if adding chemotherapy after surgery helped prevent the cancer from coming back. They found that chemotherapy only improved survival for patients with high-r…

This completed observational study looked at 3,000 people with advanced non-small cell lung cancer who received immunotherapy plus chemotherapy. Researchers built a model using chest CT scans, lung function tests, and immune markers to predict how well the treatment would work an…

This study looked at 535 people in France with advanced non-small cell lung cancer who were given nivolumab after at least one round of chemotherapy. Researchers wanted to see how well the drug worked, how long it kept cancer from getting worse, and what side effects occurred in …

This study looked at 212 adults with advanced non-small cell lung cancer who received the drug nivolumab after chemotherapy. Researchers tracked how many patients were still alive 12, 24, and 36 months after starting treatment. The goal was to see how well the drug works in every…

This study looked back at medical records of 300 people with EGFR-positive non-small cell lung cancer that had spread to the brain or spinal cord. All patients were treated with the drug firmonertinib. Researchers analyzed how long the drug controlled brain tumors and explored wh…

This study tested whether an automated system can grow cancer cells from patient samples (blood, fluid, or tumor tissue) inside chicken eggs. Researchers aimed to see if at least half of the samples would successfully grow. The goal is to create a better, cheaper way to study can…

This study looked at how the lung cancer drug AZD9291 (osimertinib) affects the breakdown of simvastatin, a common cholesterol medicine, in 52 adults with a specific type of advanced lung cancer (EGFR mutation-positive NSCLC) that had stopped responding to earlier treatments. The…

This study looked at how itraconazole, an antifungal medication, affects the levels of the lung cancer drug AZD9291 in the body. It involved 39 adults with advanced EGFR-mutant non-small cell lung cancer whose disease had worsened after previous treatments. The goal was to unders…

This study observed conversations between 37 lung cancer patients and their doctors to create a shared decision-making tool. The tool is designed to help patients who have had surgery decide whether to pursue additional treatment. Researchers aim to improve patient satisfaction b…

This completed study examined tumor samples from 3820 people with advanced solid tumors to find how many have NTRK gene fusions. Researchers used genetic testing to identify these rare changes. The study did not test any treatment, but aims to guide future targeted therapy decisi…

This study looked at 62 people with ALK-positive lung cancer whose tumors had stopped responding to newer targeted drugs. Instead of a tissue biopsy, researchers used a blood test (liquid biopsy) to find genetic changes that cause resistance. The goal was to better understand the…

This completed study looked at gene changes in 182 people with advanced lung cancer whose disease got worse after first-line treatment with Osimertinib. Researchers collected tissue and blood samples to understand why the drug stopped working. The goal is to use this information …